Intradigm has found its lead RNAi-based drug candidate in ICS-283, and while the drug’s target — the VEGF pathway — is nothing new in the RNAi field, the company is likely to pursue a novel indication for the compound.
Intradigm has found its lead RNAi-based drug candidate in ICS-283, and while the drug’s target — the VEGF pathway — is nothing new in the RNAi field, the company is likely to pursue a novel indication for the compound.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.